EUROFINS : Jefferies downgrades its opinion
Acknowledging that Eurofins shares have had a difficult 2022, the broker believes that the challenges facing the bio-analysis provider 'could continue into 2023' and sees a risk to consensus in terms of short-term results.
"The risk associated with the French diagnostics budget, laboratory strikes, combined with continued cost inflation and a gloomy outlook for pharmaceutical and food testing, prompt us to become more cautious", he explains.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction